{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T13:46:54Z","timestamp":1776520014366,"version":"3.51.2"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["5K23EY030911-03"],"award-info":[{"award-number":["5K23EY030911-03"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["R01EY033233"],"award-info":[{"award-number":["R01EY033233"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Eye Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The effectiveness of using artificial intelligence (AI) systems to perform diabetic retinal exams (\u2018screening\u2019) on preventing vision loss is not known. We designed the Care Process for Preventing Vision Loss from Diabetes (CAREVL), as a Markov model to compare the effectiveness of point-of-care autonomous AI-based screening with in-office clinical exam by an eye care provider (ECP), on preventing vision loss among patients with diabetes. The estimated incidence of vision loss at 5 years was 1535 per 100,000 in the AI-screened group compared to 1625 per 100,000 in the ECP group, leading to a modelled risk difference of 90 per 100,000. The base-case CAREVL model estimated that an autonomous AI-based screening strategy would result in 27,000 fewer Americans with vision loss at 5 years compared with ECP. Vision loss at 5 years remained lower in the AI-screened group compared to the ECP group, in a wide range of parameters including optimistic estimates biased toward ECP. Real-world modifiable factors associated with processes of care could further increase its effectiveness. Of these factors, increased adherence with treatment was estimated to have the greatest impact.<\/jats:p>","DOI":"10.1038\/s41746-023-00785-z","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T09:02:58Z","timestamp":1679907778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Effectiveness of artificial intelligence screening in preventing vision loss from diabetes: a policy model"],"prefix":"10.1038","volume":"6","author":[{"given":"Roomasa","family":"Channa","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7674-520X","authenticated-orcid":false,"given":"Risa M.","family":"Wolf","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3490-0037","authenticated-orcid":false,"given":"Michael D.","family":"Abr\u00e0moff","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-219X","authenticated-orcid":false,"given":"Harold P.","family":"Lehmann","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"785_CR1","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1016\/S2589-7500(20)30060-1","volume":"2","author":"Y Xie","year":"2020","unstructured":"Xie, Y. et al. Artificial intelligence for teleophthalmology-based diabetic retinopathy screening in a national programme: an economic analysis modelling study. Lancet Digit Health 2, e240\u2013e249 (2020).","journal-title":"Lancet Digit Health"},{"key":"785_CR2","doi-asserted-by":"publisher","first-page":"e16866","DOI":"10.2196\/16866","volume":"22","author":"J Wolff","year":"2020","unstructured":"Wolff, J., Pauling, J., Keck, A. & Baumbach, J. The Economic Impact of Artificial Intelligence in Health Care: Systematic Review. J. Med. Internet Res. 22, e16866 (2020).","journal-title":"J. Med. Internet Res."},{"key":"785_CR3","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jamaophthalmol.2020.3190","volume":"138","author":"RM Wolf","year":"2020","unstructured":"Wolf, R. M., Channa, R., Abramoff, M. D. & Lehmann, H. P. Cost-effectiveness of Autonomous Point-of-Care Diabetic Retinopathy Screening for Pediatric Patients With Diabetes. JAMA Ophthalmol. 138, 1063\u20139 (2020).","journal-title":"JAMA Ophthalmol."},{"key":"785_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.oret.2020.06.016","volume":"5","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Diabetic Retinopathy Screening with Automated Retinal Image Analysis in a Primary Care Setting Improves Adherence to Ophthalmic Care. Ophthalmol. Retin. 5, 71\u201377 (2020).","journal-title":"Ophthalmol. Retin."},{"key":"785_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/1932296820967011","volume":"16","author":"SD Fuller","year":"2020","unstructured":"Fuller, S. D. et al. Five-Year Cost-Effectiveness Modeling of Primary Care-Based, Nonmydriatic Automated Retinal Image Analysis Screening Among Low-Income Patients with Diabetes. J. Diabetes Sci. Technol. 16, 415\u201327 (2020). 1932296820967011.","journal-title":"J. Diabetes Sci. Technol."},{"key":"785_CR6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/bmj.319.7211.652","volume":"319","author":"B Haynes","year":"1999","unstructured":"Haynes, B. Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving. BMJ 319, 652\u2013653 (1999).","journal-title":"BMJ"},{"key":"785_CR7","unstructured":"World Health Organization (2016) Monitoring and evaluating digital health interventions: a practical guide to conducting research and assessment. World Health Organization. https:\/\/apps.who.int\/iris\/handle\/10665\/252183. License: CC BY-NC-SA 3.0 IGO"},{"key":"785_CR8","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/j.ophtha.2021.08.023","volume":"129","author":"MD Abr\u00e0moff","year":"2022","unstructured":"Abr\u00e0moff, M. D. et al. Foundational Considerations for Artificial Intelligence Using Ophthalmic Images. Ophthalmology 129, e14\u2013e32 (2022).","journal-title":"Ophthalmology"},{"key":"785_CR9","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1057\/s41271-021-00319-5","volume":"42","author":"NM Thomasian","year":"2021","unstructured":"Thomasian, N. M., Eickhoff, C. & Adashi, E. Y. Advancing health equity with artificial intelligence. J. Public Health Policy 42, 602\u2013611 (2021).","journal-title":"J. Public Health Policy"},{"key":"785_CR10","unstructured":"FDA-approved A.I.-based algorithms. https:\/\/medicalfuturist.com\/fda-approved-ai-based-algorithms\/ Accessed March, 2022."},{"key":"785_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-018-0040-6","volume":"1","author":"MD Abr\u00e0moff","year":"2018","unstructured":"Abr\u00e0moff, M. D., Lavin, P. T., Birch, M., Shah, N. & Folk, J. C. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. npj Digit. Med. 1, 39 (2018).","journal-title":"npj Digit. Med."},{"key":"785_CR12","unstructured":"FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-permits-marketing-artificial-intelligence-based-device-detect-certain-diabetes-related-eye. Updated 04\/12\/2018. Accessed March 2022."},{"key":"785_CR13","doi-asserted-by":"publisher","first-page":"e2134254","DOI":"10.1001\/jamanetworkopen.2021.34254","volume":"4","author":"E Ipp","year":"2021","unstructured":"Ipp, E. et al. Pivotal Evaluation of an Artificial Intelligence System for Autonomous Detection of Referrable and Vision-Threatening Diabetic Retinopathy. JAMA Netw. Open. 4, e2134254\u2013e2134254 (2021).","journal-title":"JAMA Netw. Open."},{"key":"785_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2337\/dc20-1671","volume":"44","author":"RM Wolf","year":"2021","unstructured":"Wolf, R. M. et al. The SEE Study: Safety, Efficacy, and Equity of Implementing Autonomous Artificial Intelligence for Diagnosing Diabetic Retinopathy in Youth. Diabetes Care. 44, 781\u2013787 (2021).","journal-title":"Diabetes Care."},{"key":"785_CR15","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1017\/S0266462321001732","volume":"38","author":"D Husereau","year":"2022","unstructured":"Husereau, D. et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Int. J. Technol. Assess. Health Care. 38, e13 (2022).","journal-title":"Int. J. Technol. Assess. Health Care."},{"key":"785_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","volume":"24","author":"Z Philips","year":"2006","unstructured":"Philips, Z., Bojke, L., Sculpher, M., Claxton, K. & Golder, S. Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment. PharmacoEconomics 24, 355\u2013371 (2006).","journal-title":"PharmacoEconomics"},{"key":"785_CR17","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2016.17216","volume":"316","author":"V Gulshan","year":"2016","unstructured":"Gulshan, V. et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. Jama 316, 2402\u20132410 (2016).","journal-title":"Jama"},{"key":"785_CR18","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1016\/S2589-7500(20)30003-0","volume":"2","author":"H-E Kim","year":"2020","unstructured":"Kim, H.-E. et al. Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multireader study. Lancet Digit. Health 2, e138\u2013e148 (2020).","journal-title":"Lancet Digit. Health"},{"key":"785_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1470-2045(19)30738-7","volume":"21","author":"P Str\u00f6m","year":"2020","unstructured":"Str\u00f6m, P. et al. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncol. 21, 222\u2013232 (2020).","journal-title":"Lancet Oncol."},{"key":"785_CR20","doi-asserted-by":"publisher","first-page":"m3216","DOI":"10.1136\/bmj.m3216","volume":"370","author":"JL Kwan","year":"2020","unstructured":"Kwan, J. L. et al. Computerised clinical decision support systems and absolute improvements in care: meta-analysis of controlled clinical trials. Bmj 370, m3216 (2020).","journal-title":"Bmj"},{"key":"785_CR21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla, T. A., Bracha, P., Pollack, J. & Williams, D. F. Real-world Outcomes of Anti\u2013Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States. Ophthalmol. Retin. 2, 1179\u20131187 (2018).","journal-title":"Ophthalmol. Retin."},{"key":"785_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla, T. A. et al. Real-world Outcomes of Anti\u2013Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States. Ophthalmol. Retin. 2, 645\u2013653 (2018).","journal-title":"Ophthalmol. Retin."},{"key":"785_CR23","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1136\/bmj.299.6709.1198","volume":"299","author":"TE Rohan","year":"1989","unstructured":"Rohan, T. E., Frost, C. D. & Wald, N. J. Prevention of blindness by screening for diabetic retinopathy: a quantitative assessment. Br. Med. J. 299, 1198\u20131201 (1989).","journal-title":"Br. Med. J."},{"key":"785_CR24","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.2337\/dc19-0968","volume":"43","author":"KM Pantalone","year":"2020","unstructured":"Pantalone, K. M. et al. The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model. Diabetes Care. 43, 1910\u20131919 (2020).","journal-title":"Diabetes Care."},{"key":"785_CR25","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMsa2032271","volume":"384","author":"M Fang","year":"2021","unstructured":"Fang, M., Wang, D., Coresh, J. & Selvin, E. Trends in diabetes treatment and control in US adults, 1999\u20132018. N. Engl. J. Med. 384, 2219\u20132228 (2021).","journal-title":"N. Engl. J. Med."},{"key":"785_CR26","doi-asserted-by":"publisher","first-page":"e001154","DOI":"10.1136\/bmjdrc-2019-001154","volume":"8","author":"G Bresnick","year":"2020","unstructured":"Bresnick, G. et al. Adherence to ophthalmology referral, treatment and follow-up after diabetic retinopathy screening in the primary care setting. BMJ Open Diabetes Res. Care. 8, e001154 (2020).","journal-title":"BMJ Open Diabetes Res. Care."},{"key":"785_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2337\/dc18-0828","volume":"42","author":"SR Benoit","year":"2019","unstructured":"Benoit, S. R., Swenor, B. & Geiss, L. S. Eye Care Utilization Among Insured People With Diabetes in the U.S., 2010-2014. Diabetes Care 42, 427\u2013433 (2019).","journal-title":"Diabetes Care"},{"key":"785_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archophthalmol.2008.567","volume":"127","author":"DJ Lee","year":"2009","unstructured":"Lee, D. J. et al. Reported Eye Care Utilization and Health Insurance Status Among US Adults. Arch. Ophthalmol.-Chic. 127, 303\u2013310 (2009).","journal-title":"Arch. Ophthalmol.-Chic."},{"key":"785_CR29","unstructured":"(NCQA) NCfQA. HEDIS Measurement Year 2020 and Measurement Year 2021. Volume 2L Technical Specifications for Health Plans. (National Committee for Quality Assurance (NCQA), Washington DC, 2020)."},{"key":"785_CR30","unstructured":"American Diabetes Association: Statistics About Diabetes. https:\/\/www.diabetes.org\/about-us\/statistics\/about-diabetes. Updated 2\/4\/2022. Accessed April 2022."},{"key":"785_CR31","unstructured":"Type 2 Diabetes. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/diabetes\/basics\/type2.html. Published 2021. Accessed April 2022."},{"key":"785_CR32","unstructured":"If You\u2019re Blind or Have Low Vision \u2014 How We Can Help. Social Security Administration. https:\/\/www.ssa.gov\/pubs\/EN-05-10052.pdf. Published 2022. Accessed April 2022."},{"key":"785_CR33","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.2147\/OPTH.S64200","volume":"8","author":"C Hirneiss","year":"2014","unstructured":"Hirneiss, C. The impact of a better-seeing eye and a worse-seeing eye on vision-related quality of life. Clin. Ophthalmol. (Auckl., NZ). 8, 1703\u20131709 (2014).","journal-title":"Clin. Ophthalmol. (Auckl., NZ)."},{"key":"785_CR34","unstructured":"Primary Open-Angle Glaucoma: Screening. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/primary-open-angle-glaucoma-screening Published 2022. Accessed Oct 2022."},{"key":"785_CR35","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1001\/jama.2022.7015","volume":"327","author":"CM Mangione","year":"2022","unstructured":"Mangione, C. M. et al. Screening for Impaired Visual Acuity in Older Adults: US Preventive Services Task Force Recommendation Statement. JAMA 327, 2123\u20132128 (2022).","journal-title":"JAMA"},{"key":"785_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0272989X9701700205","volume":"17","author":"D Naimark","year":"1997","unstructured":"Naimark, D., Krahn, M. D., Naglie, G., Redelmeier, D. A. & Detsky, A. S. Primer on medical decision analysis: Part 5-Working with Markov processes. Med Decis. Mak. 17, 152\u2013159 (1997).","journal-title":"Med Decis. Mak."},{"key":"785_CR37","doi-asserted-by":"publisher","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel, C. J. et al. Diabetic Retinopathy Preferred Practice Pattern\u00ae. Ophthalmology 127, P66\u2013p145 (2020).","journal-title":"Ophthalmology"},{"issue":"Supplement_1","key":"785_CR38","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.2337\/dc21-S011","volume":"44","author":"Association AD.","year":"2020","unstructured":"Association AD. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes\u20142021. Diabetes Care. 44(Supplement_1), S151\u2013S167 (2020).","journal-title":"Diabetes Care."},{"key":"785_CR39","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0161-6420(81)34978-1","volume":"88","author":"Diabetic Retinopathy Study G.","year":"1981","unstructured":"Diabetic Retinopathy Study G. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of DRS findings: DRS report 8. Ophthalmology 88, 583\u2013600 (1981).","journal-title":"Ophthalmology"},{"key":"785_CR40","doi-asserted-by":"crossref","unstructured":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch. Ophthalmol. 103, 1796\u20131806 (1985).","DOI":"10.1001\/archopht.1985.01050120030015"},{"key":"785_CR41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ophtha.2014.08.047","volume":"122","author":"MJ Elman","year":"2015","unstructured":"Elman, M. J. et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 122, 375\u2013381 (2015).","journal-title":"Ophthalmology"},{"key":"785_CR42","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/eye.2001.200","volume":"15","author":"S Prasad","year":"2001","unstructured":"Prasad, S., Kamath, G. G., Jones, K., Clearkin, L. G. & Phillips, R. P. Prevalence of blindness and visual impairment in a population of people with diabetes. Eye (Lond.). 15, 640\u2013643 (2001). (Pt 5).","journal-title":"Eye (Lond.)."},{"key":"785_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-80","volume":"11","author":"N de Fine Olivarius","year":"2011","unstructured":"de Fine Olivarius, N., Siersma, V., Almind, G. J. & Nielsen, N. V. Prevalence and progression of visual impairment in patients newly diagnosed with clinical type 2 diabetes: a 6-year follow up study. BMC Public Health 11, 80 (2011).","journal-title":"BMC Public Health"},{"key":"785_CR44","doi-asserted-by":"crossref","unstructured":"Diabetes Control and Complications Trial Research Group, Nathan, D. M., et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977\u2013986 (1993).","DOI":"10.1056\/NEJM199309303291401"},{"key":"785_CR45","doi-asserted-by":"crossref","unstructured":"Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Arch. Ophthalmol. 103, 1644\u20131652 (1985).","DOI":"10.1001\/archopht.1985.01050110038020"},{"key":"785_CR46","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2337\/diacare.16.6.889","volume":"16","author":"JA Pugh","year":"1993","unstructured":"Pugh, J. A. et al. Screening for diabetic retinopathy: the wide-angle retinal camera. Diabetes Care. 16, 889\u2013895 (1993).","journal-title":"Diabetes Care."},{"key":"785_CR47","doi-asserted-by":"publisher","first-page":"8405395","DOI":"10.1155\/2016\/8405395","volume":"2016","author":"L Crossland","year":"2016","unstructured":"Crossland, L. et al. Diabetic Retinopathy Screening and Monitoring of Early Stage Disease in Australian General Practice: Tackling Preventable Blindness within a Chronic Care Model. J. Diabetes Res. 2016, 8405395 (2016).","journal-title":"J. Diabetes Res."},{"key":"785_CR48","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1089\/tmj.2019.0264","volume":"27","author":"K Stebbins","year":"2021","unstructured":"Stebbins, K., Kieltyka, S. & Chaum, E. Follow-Up Compliance for Patients Diagnosed with Diabetic Retinopathy After Teleretinal Imaging in Primary Care. Telemed. e-Health 27, 303\u2013307 (2021).","journal-title":"Telemed. e-Health"},{"key":"785_CR49","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamaophthalmol.2017.1150","volume":"135","author":"PD Jani","year":"2017","unstructured":"Jani, P. D. et al. Evaluation of Diabetic Retinal Screening and Factors for Ophthalmology Referral in a Telemedicine Network. JAMA Ophthalmol. 135, 706\u2013714 (2017).","journal-title":"JAMA Ophthalmol."},{"key":"785_CR50","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2337\/dc20-1671","volume":"44","author":"RM Wolf","year":"2021","unstructured":"Wolf, R. M. et al. The SEE Study: Safety, Efficacy, and Equity of Implementing Autonomous Artificial Intelligence for Diagnosing Diabetic Retinopathy in Youth. Diabetes Care. 44, 781\u2013787 (2021).","journal-title":"Diabetes Care."},{"key":"785_CR51","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1089\/tmj.2012.0313","volume":"19","author":"SL Mansberger","year":"2013","unstructured":"Mansberger, S. L. et al. Comparing the effectiveness of telemedicine and traditional surveillance in providing diabetic retinopathy screening examinations: a randomized controlled trial. Telemed. e-Health 19, 942\u2013948 (2013).","journal-title":"Telemed. e-Health"},{"key":"785_CR52","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/09286586.2018.1424344","volume":"25","author":"J An","year":"2018","unstructured":"An, J., Niu, F., Turpcu, A., Rajput, Y. & Cheetham, T. C. Adherence to the American Diabetes Association retinal screening guidelines for population with diabetes in the United States. Ophthalmic Epidemiol. 25, 257\u2013265 (2018).","journal-title":"Ophthalmic Epidemiol."},{"key":"785_CR53","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2337\/dc20-0413","volume":"44","author":"CC Wykoff","year":"2021","unstructured":"Wykoff, C. C. et al. Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy. Diabetes Care. 44, 748\u201356 (2021).","journal-title":"Diabetes Care."},{"key":"785_CR54","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1001\/jama.2020.23027","volume":"324","author":"AN Antoszyk","year":"2020","unstructured":"Antoszyk, A. N. et al. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: a randomized clinical trial. Jama 324, 2383\u20132395 (2020).","journal-title":"Jama"},{"key":"785_CR55","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/dia.2018.0384","volume":"21","author":"NC Foster","year":"2019","unstructured":"Foster, N. C. et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol. Ther. 21, 66\u201372 (2019).","journal-title":"Diabetes Technol. Ther."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00785-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00785-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00785-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T09:10:50Z","timestamp":1679908250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00785-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["785"],"URL":"https:\/\/doi.org\/10.1038\/s41746-023-00785-z","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"12 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.C.: none. R.W.: Research support Dexcom. M.D.A.: reports the following competing interests: Investor, Director, Consultant of Digital Diagnostics Inc, Coralville, IA; patents and patent applications assigned to the University of Iowa and Digital Diagnostics that are relevant to the subject matter of this paper. H.P.L.: None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}